Skip to content
Innova Captab logo

Innova Captab

INNOVACAP NSE
₹1,035.00 +31.70 (+3.16%)
P/E
38.46
View as Markdown
MCP
Close 4 Nov 2026 ₹1,035.00 +232.05 +28.9% 1Y
Start ₹802.95

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
15.00%
Debt to Equity
0.32
EPS (TTM)
₹26.91
Book Value
₹190.61
Market Cap
—
P/E (TTM)
38.46
P/B
5.43
ROE
13.70%
Dividend Yield
0.20%
EBITDA
₹250 Cr
52W High
₹1,353.50
52W Low
₹622.00
Day Range
₹962.20 – ₹1,050.70
Volume
62,436

Peer Comparison

Healthcare › Pharmaceuticals

Innova Captab peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Innova Captab (this company)
₹1,035.0038.46₹5,672 Cr5.430.20%13.70%15.00%₹1,749 Cr₹154 Cr
Median 8 companies₹1,587.7038.64₹1,25,337 Cr5.100.44%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

49 Average

Data confidence 100/100

insider_selling

Category scores

Quality
42
Weak
Returns, margins, earnings quality 22% weight
Valuation
50
Average
Cheap vs sector & own history 24% weight
Growth
85
Strong
Sales & profit trajectory 9% weight
Financial Health
40
Weak
Solvency, leverage, coverage 9% weight
Momentum
53
Average
Trend strength, vol-adjusted 12% weight
Ownership
47
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 32.5% CAGR over last 5 years

Weaknesses

1
  • Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBullish667
OscillatorsBullish162
Moving AveragesNeutral505

Key readings

RSI (14)
45.02
Neutral
MACD (12,26,9)
−29.19
Bullish
SMA (50)
1,110.14
Bearish
SMA (200)
893.88
Bullish

As of

Analyst Rating

Based on 2 analysts
BUY100%

2 of 2 analysts rate Buy, 0 Hold, 0 Sell.

As of

BUY
2
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+31.73%
3Y+20.74%
1Y+31.03%
TTM+34.44%

Net profit

Net profit growth by window
5Y+32.91%
3Y+27.52%
1Y+10.16%
TTM+18.46%

Operating cash flow

Operating cash flow growth by window
5Y+22.74%
3Y+20.42%
1Y+82.81%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y+1.77 pp
3Y+2.60 pp
1Y−0.04 pp
TTM−0.33 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2019₹356 Cr
Mar 2020₹373 Cr
Mar 2021₹411 Cr
Mar 2022₹801 Cr
Mar 2023₹926 Cr
Mar 2024₹1,081 Cr
Mar 2025₹1,244 Cr
Mar 2026₹1,630 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2019₹20.00 Cr
Mar 2020₹28.00 Cr
Mar 2021₹34.00 Cr
Mar 2022₹64.00 Cr
Mar 2023₹68.00 Cr
Mar 2024₹94.00 Cr
Mar 2025₹128 Cr
Mar 2026₹141 Cr

Analyst Forecasts

Forecast For
Sep 26 consensus · EBITDA
₹74.80 Cr −0.4% vs Jun 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 31 Jul 2026
AI opinion · based on fundamentals
Risk medium

Innova Captab is a pharmaceutical CDMO with a market cap of ₹5,520 crore, trading at a PE of 39.3x. The company delivered 31% TTM revenue growth and 32.5% profit CAGR over 5 years, while operating margins remain in the 14-15% range with a significant capex cycle of ₹450+ crore underway for its Jammu facility expansion.

Bull Case 8
  • Strong 5-year compounded sales CAGR of 32%, indicating consistent top-line momentum in the CDMO space
  • TTM revenue growth of 31% YoY, with FY26 being the highest-ever annual performance
  • 5-year profit CAGR of 32.5%, demonstrating sustained earnings compounding
  • Q3 FY25 PAT jumped 36.3% YoY to ₹34.2 crore, driven by improving CDMO business mix
  • Jammu facility with potential revenue capacity of ₹1,400-1,600 crore at optimal utilization, providing a long growth runway
  • Operating margins improved from ~12% to ~14.8% over the last three years, showing gradual margin expansion
  • Net profit grew from ₹64 crore to ₹141 crore over five years, a 2.2x increase indicating strong operating leverage
  • CDMO sector tailwinds with domestic production capability and EU-GMP certified Baddi facility enabling export market access
Bear Case 8
  • PE of 39.3x is elevated for a company with ROE of only 14-15%, implying rich valuation relative to capital efficiency
  • TTM profit growth of only 9% versus 31% revenue growth signals significant margin compression or rising costs in recent quarters
  • Depreciation surged from ₹15.96 crore to ₹45.18 crore, a 183% increase, as heavy capex begins weighing on profitability
  • Company may be capitalizing interest costs, which flatters reported profits and understates true borrowing burden
  • Interest expense volatility — ranging from ₹2.4 crore to ₹21.5 crore across years — suggests lumpy debt management
  • Capex of ₹450+ crore is substantial relative to ₹5,520 crore market cap, creating execution risk if utilization ramps slowly
  • Dividend yield of just 0.21% offers negligible income return, with capital allocation tilted entirely toward reinvestment
  • 3-year ROE averaging 15% and declining to 14% in the last year suggests capital efficiency is under pressure during the expansion phase

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

153d ago

TL;DR: Innova Captab delivered a strong FY26 with 31% revenue growth driven by both CDMO and a surging Branded Generics segment. Margins expanded at EBITDA level though PAT growth was more modest at 9.9%. No material headwinds are visible in recent filings. With 20%+ growth guidance for FY27 and rising export contribution, the momentum appears intact and improving.

Positives 4
  • Strong 31% revenue growth FY26 Jun 4

    Consolidated revenue rose 31.1% to ₹1,630.02 crore, EBITDA up 26.3% to ₹250.34 crore, and PAT grew 9.9% to ₹140.92 crore in FY26.

  • Branded Generics surges 51.4% Jun 4

    Branded Generics segment revenue surged 51.4% to ₹496.67 crore while CDMO grew 23.8% to ₹1,133.35 crore in FY26.

  • 20%+ growth guidance for FY27 May 15

    Management guided 20%-plus revenue growth for FY27 during the Q4 FY26 earnings call, with the Jammu facility achieving ~₹300 crores revenue.

Neutral 4
  • 22nd AGM scheduled June 29 Jun 4

    AGM convened for June 29, 2026 via VC/OAVM with agenda including re-appointment of directors and auditors; e-voting from June 26–28.

  • Auditor and director re-appointments May 25

    Board approved re-appointment of statutory auditors B S R & Co. LLP for five years from FY27 and director Vinay Lohariwala for a second term effective March 2027.

  • Investor conference attendance May 20

    Innova Captab to attend 360 ONE Capital 16th Annual Global Investor Conference in Mumbai on May 27, 2026.

Quarterly Results

₹ Cr
INNOVACAP quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
233
283
302
263
294
318
316
315
352
380
450
448
471
Expenses
202
242
258
225
252
268
270
267
299
329
381
383
398
Operating Profit
31
40
45
38
42
50
47
48
52
52
69
65
73
OPM %
13%
14%
15%
14%
14%
16%
15%
15%
15%
14%
15%
15%
16%
Other Income
1
3
2
6
2
2
4
3
4
4
2
2
2
Interest
5
9
7
1
0
0
0
2
3
6
4
5
4
Depreciation
3
5
5
3
5
5
5
10
11
11
11
11
12
PBT
25
30
35
40
39
47
46
39
43
39
56
51
59
Tax %
28%
24%
29%
27%
25%
25%
25%
25%
27%
24%
24%
25%
25%
Net Profit
18
23
25
29
29
35
34
30
31
30
42
38
44
EPS (₹)
3.66
4.77
4.39
5.02
5.15
6.12
5.98
5.17
5.42
5.18
7.37
6.65
7.71

Profit & Loss

₹ Cr
INNOVACAP profit and loss, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
356
373
411
801
926
1,081
1,244
1,630
1,749
Expenses
315
322
356
704
813
927
1,057
1,387
1,490
Operating Profit
41
51
54
96
114
154
186
243
259
OPM %
11%
14%
13%
12%
12%
14%
15%
15%
15%
Other Income
0
1
1
3
9
12
12
7
9
Interest
6
5
4
6
20
21
2
17
18
Depreciation
11
10
6
8
11
16
25
45
46
PBT
25
38
46
86
92
130
171
188
205
Tax %
20%
26%
26%
25%
26%
27%
25%
25%
—
Net Profit
20
28
34
64
68
94
128
141
154
EPS (₹)
4.14
5.81
7.19
13.32
14.16
16.49
22.41
24.63
26.91
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
8%
—

Balance Sheet

₹ Cr
INNOVACAP balance sheet, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
12
12
12
12
48
57
57
57
Reserves
70
98
133
197
229
774
902
1,034
Borrowings
72
54
46
199
237
245
338
344
Other Liabilities
68
81
179
167
191
240
271
401
Total Liabilities
223
245
370
575
704
1,316
1,568
1,836
Fixed Assets
78
73
79
183
183
358
830
842
CWIP
0
0
7
0
22
341
23
16
Investments
0
0
0
0
0
0
0
41
Other Assets
144
172
283
392
500
617
716
938
Total Assets
223
245
370
575
704
1,316
1,568
1,836

Cash Flow

₹ Cr
INNOVACAP cash flow, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
19
31
42
59
67
146
64
117
Investing
−9
−6
−20
−188
−91
−499
−152
−107
Financing
−9
−23
−19
125
27
361
92
−22
Net Cash Flow
1
1
3
−5
3
8
4
−12
Free Cash Flow
11
27
23
−21
−11
−141
−108
55
CFO/EBITDA
68
79
101
83
76
113
47
59

Ratios

INNOVACAP financial ratios, annual
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
93
85
123
97
104
97
97
98
Inventory Days
50
84
107
76
77
91
119
125
Days Payable
80
92
132
86
105
113
115
141
Cash Conversion Cycle
64
77
99
87
77
75
101
82
Working Capital Days
30
45
39
37
58
77
81
86
ROCE %
—
26%
28%
31%
24%
19%
15%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Innova Captab insights

68 extracted metrics across FY19–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 50.90%
  • Public 27.41%
  • DIIs 19.16%
  • Others 1.68%
  • FIIs 0.84%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Innova Captab

What does Innova Captab Ltd do?
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.
Where is Innova Captab Ltd (INNOVACAP) listed?
Innova Captab Ltd trades as INNOVACAP on the NSE and under code 544067 on the BSE.
Which sector does Innova Captab Ltd belong to?
Innova Captab Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Innova Captab Ltd?
Innova Captab Ltd trades at a PE ratio of 38.46 as of 4 Nov 2026, on earnings per share of ₹26.91, against a book value of ₹190.61 per share.
What is the 52-week high and low of Innova Captab Ltd?
Over the last 52 weeks Innova Captab Ltd has traded between ₹622 and ₹1,353.5 as of 4 Nov 2026.
Does Innova Captab Ltd pay dividends?
Innova Captab Ltd has a dividend yield of 0.20%.
What is the Return on Equity (ROE) of Innova Captab Ltd?
Innova Captab Ltd reported a return on equity of 13.70%. Its debt-to-equity ratio is 0.32.

Company Information

Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.

Website innovacaptab.com
Listed 29 Dec 2023
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/INNOVACAP.md for Innova Captab Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month